<?xml version="1.0" encoding="UTF-8"?>
<ack>
 <title>Acknowledgements</title>
 <p>The author thanks employees of WuXi Biologics including Chris Chen, Sherry Gu, Jiexing Cai and Ying Hu for close collaborations and discussions regarding strategies for accelerating development timelines for initial clinical trials. Colleagues at Vir Biotechnology including Kristen Koterba Douglas, Davide Corti, Lori Houle, Jay Howlett, Irene Pleasure, Todd Renshaw, Lynne Krummen and Michael Kamarck provided invaluable input to the concepts and strategies described in this manuscript. A broad group of biopharmaceutical technical development leaders also contributed during many years of benchmarking.</p>
</ack>
